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Jurkat cellsInositol hexaphosphate (InsP6) is present in cereals, legumes, nuts and seed oils and is biologically active against
some tumor and cancer cells. Herein, this study aimed at evaluating the cellular toxicity, antiproliferative activity
and effects on cell cycle progression of free InsP6 and InsP6–Ni(II) of leukemic T (Jurkat) and normal human cells.
Treatments with InsP6 at concentrations between 1.0 and 4.0 mM signiﬁcantly decreased the viability of Jurkat
cells, but showed no cytotoxic effect on normal human lymphocytes. Treatment with InsP6–Ni(II) complex at
concentrations between 0.05 and 0.30 mM showed an anti-proliferative dose and a time-dependent effect,
with signiﬁcantly reduced cell viability of Jurkat cells but showed no cytotoxic effect on normal human lympho-
cytes as compared to the control. Ni(II) free ion was toxic to normal cells while InsP6–Ni(II) had no cytotoxic ef-
fect. The InsP6–Ni(II) complex potentiated (up to 10×) the antiproliferative effect of free InsP6 on Jurkat cells. The
cytometric ﬂow assay showed that InsP6 led to an accumulation of cells in the G0/G1 phase of the cell cycle, ac-
companied by a decrease in the number of cells in S and G2/M phases, whereas InsP6–Ni(II) has led to an accu-
mulation of cells in the S and G2/M phases. Our ﬁndings showed that InsP6–Ni(II) potentiates cytotoxic effects of
InsP6 on Jurkat cells and may be a potential adjuvant in the treatment of cancer.
© 2015 Elsevier Ltd. All rights reserved.1. Introduction
Inositol hexaphosphate, InsP6, also known as phytic acid, is present
in cereals, legumes, nuts and seeds, accounting for up to 85% of total
phosphorus in cereals and leguminous plants (Graf and Eaton, 1990;
Tsao et al., 1997). InsP6 can also be found in humans at a physiological
concentration that can reach up to 100 μM (Vucenik et al., 2005). In
vitro studies have reported the anti-carcinogenic activity of InsP6 on dif-
ferent types of tumors and cancer cell lines as it inhibits cell prolifera-
tion and differentiation of malignant cells, restoring the normal
phenotype. InsP6 acts speciﬁcally on the p21 proteins involved in the
cell cycle of cancer cells (Kim et al., 2007). In addition, it induces G1
phase arrest and causes a signiﬁcant decrease of the S phase of human
cancer cell lines by modulating cyclins and cdks, up-regulating
p27Kip1 and p21WAF1/CIP1, and decreasing the retinoblastoma (Rb)
protein phosphorylation (Vucenik and Shamsuddin, 2006). Exposing
MCF-7 breast cancer cells to InsP6 has shown to block the proliferation
of such cells through a PKCδ-dependent increase in p27Kip1 and a sig-
niﬁcant decrease in retinoblastoma protein (pRb) phosphorylation(Vucenik et al., 2005). InsP6 has potent inhibitory effects on the pro-
liferation of HT-29 cells by modulating the expression of special cell
cycle regulators (Tian and Song, 2006). Different concentrations of
InsP6 in HT-29 cells increased the transcription of p53 and p21
Waf1 genes. The ability of InsP6 to arrest the cell cycle may be medi-
ated by the transcriptional up-regulation of the p53-responsive
p21(WAF1) gene (Węglarz et al., 2006).
Inositol tetra and pentaphosphate, InsP4 and InsP5, respectively, also
induce the apoptosis of cancer cells; however, InsP6 is more efﬁcient
and has shown to promote apoptosis of some cancer cells through dif-
ferentmechanisms (Agarwal et al., 2009). T98G glioblastoma cells treat-
ed with InsP6 presented an increased expression of Bax (a proapoptic
gene) and a decrease in the expression of Bcl-2 (an antiapoptic gene),
caspase-3 activation and cellular death induced by apoptosis
(Karmakar et al., 2007). Another mechanism of InsP6 has been demon-
strated using a colon cancer cell line (Caco-2) stimulated by interleukin-
1β. The InsP6 inﬂuences constitutive expression of metalloproteinase,
MMP and TIMP (tissue inhibitors of MMPs) genes and downregulates
IL-1β stimulated transcription of some of these genes. InsP6 exerts its
anti-metastatic activity through modulation of MMP and TIMP genes
expression to prevent cancer cell migration and invasion (Kapral et al.,
2012). Physiological intestinal concentrations of InsP6 may have an
2082 E.M. de Lima et al. / Toxicology in Vitro 29 (2015) 2081–2088inhibitory effect on IL-8 secretion by Caco-2 cells and one of the mech-
anisms of its action is the inhibition of PTK signaling cascade. The PTKs
could be one of the molecular targets for InsP6 effects in the intestinal
epithelial cells (Wawszczyk et al., 2013).
In vivo studies have shown that InsP6 combinedwith basic ﬁbroblast
growth factor, completely inhibited the formation of new blood vessels
in mice. The mechanism of action of InsP6 is also related to the regula-
tion of angiogenesis. New blood vessels are responsible for providing
nutrients and oxygen to the tumor, in addition to promoting the spread
of metastatic cells (Vucenik et al., 2004). When topically applied, InsP6
induces the apoptotic machinery by modulating the expression of mt
p53, Bcl-2, and caspase activity (Singh and Gupta, 2008). According to
Williams et al. (2011), the topical application of InsP6 followed by expo-
sure to UVB irradiation on SKH1 hairlessmice decreased the tumor inci-
dence and proliferation when compared with the control group. A
recent studyusing quantitative high-resolution 1H-NMR onprostate tis-
sue extracts showed that InsP6 signiﬁcantly decreased the glucose me-
tabolism and the synthesis of membrane phospholipid, in addition to
causing an increase on myo-inositol levels in the prostate (Raina et al.,
2013).
Several studies have related the ability of InsP6 to reduce the risk of
developing cancer and also to inhibit cell proliferation and tumor pro-
gression in animal models (Ferry et al., 2002; Deliliers et al., 2002;
Rizvi et al., 2006; Karmakar et al., 2007; Agarwal et al., 2009;
Kolappaswamy et al., 2009; Wawszczyk et al., 2013). The activity of
some metal complexes against tumors using both in vitro and in vivo
protocols is already known and recognized worldwide (Immel et al.,
2011; Côrte-Real et al., 2013; Palanimuthu et al., 2013; Tan et al.,
2010; Milenković et al., 2013). Studies have reported the characteriza-
tion and stability of some InsP6 complexes with transition metal ions,
including Ni(II) (De Carli et al., 2006, 2009; Quirrenbach et al., 2009).
However, no studies were found in the literature relating the bioactivity
of InsP6 coordination compounds.
Based on these facts, this study aimed at evaluating the cellular tox-
icity, antiproliferative activity and effects on cell cycle progression of
free InsP6 and InsP6–Ni(II) in leukemic T cells (Jurkat) as well as in nor-
mal human cells.2. Materials and methods
2.1. Chemicals
All analytical grade reagents were used without further puriﬁcation.
Milli-Q (Millipore) water was used to prepare all solutions. InsP6
(dodecassodium salt), 3-(4.5-dimethylthiazol-2yl)-2-5-diphenyl-2H
tetrazolato bromine (MTT), propidium iodide (PI) and trypan blue
were obtained from Sigma Chemical, Co. (St. Louis, MO, USA).
NiCl2·6H2O and vincristine sulfate (Tecnocris®), were obtained from
Merck (Darmstadt, Germany) and Eurofarma Ltda (São Paulo, SP,
Brazil), respectively. The InsP6–Ni(II) complex was synthesized and
characterized as previously described (De Carli et al., 2006, 2009).2.2. Cell culture
The Jurkat cells were routinely cultivated in RPMI 1640 (Cultilab) at
pH 7.4 supplemented with 10% fetal bovine serum (FBS, Vitrocell), 0.1%
of antibioticmix (10,000 units penicillin and 10mgmL−1 streptomycin,
Vitrocell) and sodium bicarbonate (2mgmL−1). Theywere placed in an
incubator humidiﬁed at 37 °C with 5% CO2. All the solutions used in the
cell culture treatment were prepared in FBS-free medium, ﬁltrated
using a 0.22 μm membrane (Milex®GP, Millipore) and stored at 4 °C
until use. The leukemic cell line was chosen to be the experimental
model in the current study because it is highly susceptible to InsP6
(Matejuk and Shamsuddin, 2010).2.3. Isolation of normal human lymphocytes
In accordance with authorization from the Institute's Ethics Com-
mission (Opinion No 66/2011, Protocol: 06065/11), peripheral blood
samples were collected from healthy, non-smoking male volunteers,
who had fasted for 12 h. Mononuclear cells (lymphocytes and mono-
cytes) were separated with Histopaque reagent 1077. The layer of
mononuclear cells was removed and washed twice with phosphate
buffered saline solution (PBS). The cells were re-suspended in RPMI
1640 pH 7.4 culture supplementedwith 10% FBS, 10,000 units penicillin,
10 mg mL−1 of streptomycin and sodium bicarbonate (2 mg mL−1).
They were then seeded in culture bottles (75 cm2), and incubated for
2 h at 37 °C. After 2 h of culture, the lymphocytes present in the super-
natant were separated from the monocytes and used in the
experiments.
2.4. In vitro biological tests
2.4.1. Evaluation of the cytotoxic effect of InsP6, NiCl2 and InsP6–Ni(II) com-
plex on Jurkat cells
The Jurkat cells (1 × 105 cells mL−1) were treated with InsP6 at con-
centrations ranging from 0.250 to 4.00 mM; InsP6–Ni(II) complex at
concentrations from 0.055 to 0.220 mM; or NiCl2 at concentrations
from 0.10 to 0.60mM, in RPMImedium containing 2.5% FBS. Vincristine
sulfate (40 nM) was used as positive control. Cell viability was deter-
mined by means of two different assays: (1) trypan blue dye exclusion
test, in which the cells were counted using a Neubauer chamber after
24 and 48 h; (2) MTT reduction assay. After 24 and 48 h of treatment,
the cell suspension was transferred to 2 mL vials and centrifuged at
138 g for 5 min. The supernatant was discarded and 400 μL of a 1:10
mixture of MTT (5mgmL−1) was added to each vial. The cells were in-
cubated at 37 °C for 30 min and centrifuged again at 800 g for 10 min.
The supernatant was discarded and 200 μL of dimethyl sulfoxide were
added to solubilize the purple precipitate (formazan) and the absor-
bance was measured at 550 nm (Côrte-Real et al., 2013). The IC50
value was calculated for InsP6 and in order to compare the cytotoxicity
of each compound tested, in which InsP6–Ni(II) complex was used as a
parameter for comparison purposes. Consequently, the IC50was deﬁned
as the drug concentration (mM) inducing a 50% reduction in cellular vi-
ability through the exclusion assay performedwith trypan blue dye. The
IC50 was calculated by the Probit regression approach.
2.4.2. Evaluation of the antiproliferative effect of InsP6, NiCl2 and InsP6–
Ni(II) complex on Jurkat cells
The Jurkat cells (1 × 105 cells mL−1) were treated with InsP6 at con-
centrations ranging from 0.250 to 4.00 mM, NiCl2 0.10 to 0.60 mM and
InsP6–Ni(II) complex at concentrations ranging from 0.055 to
0.220 mM in RPMI medium with 2.5% FBS. The proliferation of Jurkat
cells was performed by quantifying the DNA content (Sellitti et al.,
2001). After 48 h of cultivation, the cell suspension was placed in 2 mL
vials and centrifuged at 550 g for 10 min at room temperature. The su-
pernatantwas removed and 0.5mL of DPAwas added to the precipitate.
This solution was incubated for 24 h and the absorbance was recorded
at 575 nm. The DPA solution consisted of 8 mL of deionized water,
0.1 mL of 1% acetaldehyde and 20mL of stock solution (1 g of diphenyl-
amine, 90 mL of glacial acetic acid and 2 mL of sulphuric acid).
2.4.3. Effect of InsP6 and InsP6–Ni(II) complex on the cell cycle progression
of Jurkat cells
The cell cycle progression assaywas performed according to a proto-
col previously described by Nicoletti et al. (1991). Brieﬂy, 106 mL−1 of
Jurkat cells were seeded into each well of a 96-well plate and after
24 h of incubation, either InsP6 (1.00, 2.00 and 4.00 mM) or InsP6–
Ni(II) complex (0.070, 0.175 and 0.300 mM) was added. The plate was
further incubated for 24 h and 48 h. Subsequently, the cells were centri-
fuged at 550×g for 20 s. The pelletwaswashedwith PBS buffer and after
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(propidium iodide 50 mg mL−1, 0.1% citrate, 0.1% Triton X-100). The
lysed cells were then incubated in the dark at 4 °C for 24 h, and used
for the analysis of the cell cycle. Propidium iodide intercalates between
bases in double stranded nucleic acids of exposed nuclei. The ﬂuores-
cence was evaluated by ﬂow cytometry (FACS Calibur— Becton Dickin-
son Systems, San Jose, USA) by using CellQuest software (Becton
Dickinson Systems). Twenty thousand events were evaluated per
experiment.
2.4.4. Evaluation of the cytotoxic effect of InsP6 and InsP6–Ni(II) complex on
normal human lymphocytes
The cell viabilitywas determined after 48 h of treatment through the
trypan blue dye exclusion test and MTT assay, as previously described
above. The lymphocytes were seeded in 24-well plates at a concentra-
tion of 2 × 105 cells L−1 and treated with InsP6 (2.00 to 6.00 mM);
InsP6–Ni(II) complex (0.110 to 0.335mM); NiCl2 (0.30mM); or vincris-
tine (4.0 × 10−5 mM) with SFB at 2.5%.
2.5. Statistical analysis
The experiments were performed at least three times, and the re-
sults are representative of one experimentwith 3–4 replicates to assure
the repeatability and reproducibility of the generated data. These re-
sults are presented in the supplementary material. Statistical and
graphical information was determined using GraphPad Prism software
(GraphPad Software Incorporated). Multiple-group comparisons were
performed using a one-way analysis of variance followed by a post hoc
intergroup comparison by the Tukey's test. Probability values below
0.05 were considered statistically signiﬁcant (Granato et al., 2014).
3. Results
3.1. Evaluation of the cytotoxic effect of InsP6, NiCl2, InsP6–Ni(II) complex on
Jurkat cells
Fig. 1A and B show the results of the cell viability assays for treat-
ment with InsP6 for 24 and 48 h. The concentrations from 0.25 to
0.50 mM presented no cytotoxic effect on the Jurkat cells. The highest
concentrations showed a signiﬁcant decrease in cell viability compared
to the control (p b 0.05). The treatment of Jurkat cells with InsP6 at
higher concentrations showed a pronounced antiproliferative effect,
dose and time dependent. The cellular metabolism test carried out in
24 h with InsP6 (Fig. 1A) showed a decrease in cell viability compared
to control only at a concentration of 4.00 mmol L−1 (13.70 ± 2.22%).
On the other hand, over 48 h, the treatment led to reduced cell viabilityFig. 1. Cytotoxicity of InsP6 on Jurkat cells. Cell viability was determined using theMTT reduction
results are representative of one experiment with n= 3–4 replicates and were reproducible in
when one-way ANOVA followed by Tukey's post hoc test was applied in relation to the controlfrom the concentration of 1.00 to 4.00 mmol L−1, although it was only
statistically signiﬁcant for concentrations of 2.00 and 4.00 mmol L−1.
In these concentrations, there was a dose-dependent reduction in cell
viability of 12.93 ± 6.64 and 82.86 ± 0.61%, respectively. The test of
cell viability, assessed by the exclusion of trypan blue dye, (Fig. 1B), con-
ﬁrmed the results obtained for theMTT assay. The concentrations of 2.0
and 4.0 mM during 24 h of treatment promoted a reduction in cell via-
bility compared to control of 31.67 ± 9.28% and 53.33 ± 1.67%, respec-
tively. Over 48 h, the reduction of viability was even more pronounced,
rising to 47.66±2.01% and 88.37±2.33%, respectively. Treatmentwith
vincristine, positive control of cycle-speciﬁc cell death, promoted the re-
duction of cell viability above 50%.
Fig. 2 shows the results of Ni(II) ions cytotoxicity on Jurkat cells. The
Ni(II) ions strongly reduced the cell viability in a dose and time-
dependent manner in both MTT reduction assays and trypan blue dye
exclusion assays.
Fig. 2A and B show the effect of the treatmentwith InsP6–Ni(II) com-
plex on the cell viability of Jurkat cells. In these experiments we used
lower concentrations of the complex as compared to InsP6. In the MTT
reduction assay, the InsP6–Ni(II) complex at concentrations of 0.11 to
0.22 mM reduced the viability in a dose and time-dependent manner.
Over a period of treatment of 24 h a reduction of 34.66 ± 2.52 to
58.09 ± 3.28% of cell viability was observed and over a period of 48 h
a pronounced reduction was also observed, with reduction rates of
49.43 ± 2.64 to 87.52 ± 0.51%. The trypan blue dye exclusion assay
was only signiﬁcant in the treatment of 48 h; at concentrations of 0.11
to 0.22 mM the InsP6–Ni(II) complex reduced the cell viability by
61.76 ± 5.88 to 93.14 ± 2.59%, respectively. Furthermore, using the
Jurkat cell line, the IC50 values (Table 1) for the InsP6–Ni(II) complex
were statistically lower than those obtained for InsP6.
3.2. Evaluation of the cytotoxic effect of InsP6, NiCl2, InsP6–Ni(II) complex
on normal human lymphocytes
Fig. 3A and B show the cytotoxic effects of treatment with InsP6 in
normal human lymphocytes isolated from healthy volunteers. InsP6
did not present cytotoxic effects in any of the concentrations used in
treatment over 48 h. The MTT reduction and trypan blue dye exclusion
assays showed that at the highest concentration of InsP6 (6.0 mM), the
lymphocytes maintained their mitochondrial activity and membrane
integrity compared to control. The effect of vincristine in the cell viabil-
ity was similar to control.
Fig. 4A and B show the effects of treatment over 48 h with InsP6–
Ni(II) complex and NiCl2 on normal human lymphocytes. The InsP6–
Ni(II) complex did not present cytotoxic effects in any of the concentra-
tions thatwere used. However, NiCl2 at a concentration of 0.30mMwasand trypan blue dye exclusion assays and the results are expressed as amean± SEM. The
an additional experiment. The symbols # and * represent statistical differences (p b 0.05)
, over 24 or 48 h, respectively.
Fig. 2. Cytotoxicity of InsP6–Ni(II) complex and NiCl2 on Jurkat cells. Cell viability was determined using theMTT reduction and trypan blue dye exclusion assays. The amount of Ni in the
InsP6 complex corresponds to the same concentration of NiCl2. The results are expressed as a mean ± SEM and are representative of one experiment with n = 3–4 replicates and were
reproducible in an additional experiment. The symbols # and * represent statistical differences (p b 0.05)whenone-wayANOVA followed by Tukey's post hoc testwas applied in relation to
the control, over 24 or 48 h, respectively.
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14.41% in the MTT reduction and trypan blue dye assays, respectively.3.3. Evaluation of the antiproliferative and cell cycle progression effects of
InsP6 and InsP6–Ni(II) complex on Jurkat cells
Fig. 5A and B show the DNA content of the Jurkat culture over 48 h of
treatment with InsP6 and InsP6–Ni(II) complex, respectively. The DNA
content was evaluated in an indirect method in order to determine
the index of proliferation. The treatment with InsP6 showed a dose-
dependent antiproliferative effect (Fig. 5A). In the concentration of
4.0 mM of InsP6, a reduction in DNA content of 54.22 ± 0.46% was ob-
served. Treatmentwith vincristine promoted the reduction of prolifera-
tion above 40%. Similarly, the treatment with InsP6–Ni(II) complex
showed a dose-dependent antiproliferative effect (Fig. 5B); however,
as mentioned, lower concentrations were used. A signiﬁcant reduction
of proliferation was observed at concentrations of 0.11 to 0.22 mM of
InsP6–Ni(II) complex. This result was conﬁrmed by the lower DNA con-
tent, which was, respectively 21.91 ± 0.68 and 36.06 ± 1.22% as com-
pared to the control.
Table 2 shows the effects of InsP6 on the cell cycle progression of the
Jurkat cells. The concentrations of 2.0 and 4.0mMused in the treatment
for 24 h induced G0/G1 arrest with a concomitant decrease in cell num-
bers in the S and G2/M phases.
The effects of the InsP6–Ni(II) complex on the cell cycle progression
of the Jurkat cells are shown in Table 3. The InsP6–Ni(II) complex used
for treatment of 24 h did not induce G0/G1 arrest; however, an accumu-
lation of the cells in the G2/M phase was observed. The ﬂow cytometry
of these cells showed that concentrations of 0.175 and 0.300 mM in-
duced cellular death, which was represented by the sub G0 population.Table 1
IC50 for InsP6, NiCl2 and InsP6–Ni(II) from Jurkat culture over 48 h.
Compound IC50 (mM ± SEM)
MTT reduction assay Trypan blue exclusion assay
InsP6 2.34 ± 0.65 1.97 ± 0.53
NiCl2 0.101 ± 0.016 0.119 ± 0.011
InsP6–Ni(II) 0.104 ± 0.005 0.093 ± 0.004
The IC50 corresponds to the concentration of compounds that inhibited 50% of cell growth.
The IC50 was calculated based on a graph of cellular viability obtained using the MTT re-
duction assay versus the concentration of the compounds. The IC50was calculated by Prob-
it regression. The results are expressed as a mean ± SEM and are representative of one
experiment with n = 3–4 replicates and were reproducible in an additional experiment.The proﬁle response of vincristinewas similar to that of the InsP6–Ni(II)
complex, but an increase in the sub G0 population was not observed.4. Discussion
InsP6 possesses antiproliferative activities and has therefore been
proposed as an antitumor agent (Vucenik et al., 2005; Tian and Song,
2006; Agarwal et al., 2009; Kapral et al., 2012; Deliliers et al., 2002;
Singh et al., 2003). In the sameway, Ni(II) has been described as an im-
portant cytotoxic agent and apoptosis inductor (Ada et al., 2010; Chen
et al., 2010). In the present study, InsP6 was used for the ﬁrst time in
the form of a complex with Ni(II) to enhance the efﬁcacy of this com-
pound as an antitumoral agent. Based on the evidence that leukemic
cell lines seem to be more susceptible to InsP6 than other tumor cells,
Jurkat cells were used as the experimental model to compare the effect
of pharmaceutical concentrations of InsP6, NiCl2 and InsP6–Ni(II)
complex in an experiment for 24 or 48 h (Shamsuddin et al., 1992;
Deliliers et al., 2002; Matejuk and Shamsuddin, 2010). The effect of
the InsP6–Ni(II) complex on Jurkat proliferation was more effective
when compared to InsP6 (Figs. 1 and 2). Only high concentrations of
InsP6 (up to 2.0 mmol L−1) had an inhibitory effect as compared to
NiCl2 or InsP6–Ni(II) complex (Fig. 2).
The present study corroborated earlier observations on the ability of
high concentrations of InsP6 to inhibit the cell proliferation of tumor
cells (Tian and Song, 2006; Deliliers et al., 2002; Singh et al., 2003).
We also conﬁrmed that InsP6 is not cytotoxic to normal cells (Fig. 3)
and that this result is similar to those obtained by Deliliers et al.
(2002) regarding progenitor CD34+ cells taken from the bone marrow
of healthy volunteers. These authors observed a cytotoxic effect on
chronic myeloid leukemia CD34+ cells with different doses of InsP6,
but they found no cytotoxic effects in normal cells under the same con-
ditions. A high cell viability score (80%) has been observed when using
InsP6 at a dose of 10.0 mM (Deliliers et al., 2002). We observed that a
low concentration of InsP6, data not show, stimulated the cell prolifera-
tion but this result has already been reported by Windhorst et al.
(2013). The authors compared the effect of pharmaceutical and extra-
cellular physiological InsP6 concentrations on tumor cell proliferation
using lung tumor cells (H1299). Cells incubated using a concentration
range of 1–75 μMInsP6 showed a signiﬁcant increase in the proliferation
after 48 h and 72 h in comparison with the control cells. In contrast, in-
cubation at 100 μM InsP6 for 72 h signiﬁcantly reduced the growth of
H1299 cells. Thus, the effect of InsP6 on tumor cell proliferation is
strongly concentration-dependent.
Fig. 3. Cell viability effects of InsP6 on normal human lymphocytes. Cell viabilitywas determinedusing theMTT reduction and trypan blue dye exclusion assays; the results are expressed as
amean±SEM. The results are representative of one experimentwith n=3–4 replicates andwere reproducible in an additional experiment. The symbol * represents statistical differences
(p b 0.05) when one-way ANOVA followed by Tukey's post hoc test was applied in relation to the control over 48 h of treatment.
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resulted in a pronounced antiproliferative activity; it exerted cytotoxic
activity on Jurkat cells at IC50 93 μM (66.1 μg/mL), as shown by the
trypan blue dye exclusion assay. When Jurkat T cells were treated
with InsP6–Ni(II) complex (0.055 to 0.220mM) for 24 h and 48 h, a sig-
niﬁcant reduction in cell viability was observed (Fig. 2). Likewise, the
cytotoxic effect of InsP6–Ni(II) complex on Jurkat T cells, the DNA con-
tent determination (Fig. 5), as well as the fact that the sub G0 apoptotic
cells appeared to increase in a dose-dependent manner after the treat-
mentwith InsP6–Ni(II) complex (Fig. 4). It appears that the cytotoxic ef-
fect of InsP6–Ni(II) complex on Jurkat T cells is attributable to induced
apoptotic cell death. According to Palanimuthu et al. (2013), complexes
formed by bis-(thiosemicarbazone) with copper substantially inhibit
DNA synthesis and lead to the induction of apoptosis in tumor cells
HCT116 (colorectal cancer). Tsekova et al. (2013) found that coordina-
tion compounds of Pd(II) with hematoporphyrin led to growth inhibi-
tion of human tumor cell lines. They observed that cell growth
inhibitory effects were related to the induction of programmed cell
death through apoptosis.
Once one of the most important criteria for a therapeutic drug de-
signed for cancer treatment is to have minimum or no side effects on
the normal body cells of patients undergoing chemotherapy, we tested
the InsP6–Ni(II) complex on normal human lymphocytes. The InsP6–
Ni(II) complex did not present any toxicity (Fig. 4). In addition, a high
cell viability of lymphocytes in the MTT reduction assay was observed.
This assay reﬂects the cell metabolism expressed by dehydrogenasemi-
tochondrial activity. As InsP6 is dephosphorylated to inositol in the me-
dium and after cellular uptake, we suggest that the high cell viability or
proliferation-stimulating effect of InsP6 results from an increasedFig. 4. Cell viability effects of InsP6–Ni(II) complex and NiCl2 on normal human lymphocytes. Ce
the results are expressed as a mean ± SEM. The results are representative of one experiment w
represents statistical differences (p b 0.05) when one-way ANOVA followed by Tukey's post hoproduction of inositol (Windhorst et al., 2013). So, probably even
under the experiment circumstances, the effects of inositol can be due
to the presence of inositol at a higher concentration than the level reg-
ularly found in human serum. It is noteworthy that inositol receptor
promotes the release of Ca2+ into the mitochondria, which is an essen-
tial and necessary cellular process for the efﬁcient mitochondrial respi-
ration and for the maintenance of cell bioenergetics (Cárdenas et al.,
2010). Inositol is an essential growth factor for the survival and multi-
plication of both normal and malignant human cell lines (Eagle et al.,
1957).
In fact, our experiments reveal that the InsP6–Ni(II) complex pre-
sented potent activity at lower concentrations and also exhibited a
high degree of selectivity. Speciﬁc cytotoxicity in relation to cancerous
cells is an important characteristic and is desired in antitumoral sub-
stances (Deliliers et al., 2002; Rath et al., 2013). The search for new nat-
ural substances with speciﬁc effects on cancer, and with a reduced
adverse effect on the biological functions of the body, has been the sub-
ject of studies (Li et al., 2013; Lee et al., 2013). The InsP6 stands out be-
cause it is a naturally occurring compound, which may explain its low
cytotoxicity in relation to normal cells, even when it is in the form of a
metal complexwithNi(II). InsP6 is a substance that is common to organ-
isms; it is present in the cells of all mammals, which absorb it from food
(Letcher et al., 2008; Vucenik et al., 2005; Grases et al., 2001a,b). Con-
trary to what was believed some time ago, InsP6 is not only synthesized
by plants; it has been proven that it is synthesized by mammalian cells
(Letcher et al., 2008). According to Vucenik et al. (2005), the physiolog-
ical concentration of InsP6 in humans can reach up to 100 μM. In addi-
tion, InsP6 is an important signaling molecule and it is found in all
living beings. Changes in the degree of phosphorylation are part of all viability was determined using theMTT reduction and trypan blue dye exclusion assays;
ith n = 3–4 replicates and were reproducible in an additional experiment. The symbol *
c test was applied in relation to the control over 48 h of treatment.
Fig. 5. Antiproliferative effect of InsP6 and InsP6–Ni(II) complex on Jurkat cells. The index of proliferation was determined using the DPA solution to quantify the DNA content. Results are
expressed as a mean ± SEM. The results are representative of one experiment with n = 3–4 replicates and were reproducible in an additional experiment. The symbol * represents sta-
tistical differences (p b 0.05) when one-way ANOVA followed by Tukey's post hoc test was applied in relation to the control.
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they regulate cellular functions and activities (Majerus et al., 2008).
Moreover, although it is a highly charged molecule, InsP6 may be
absorbed through the gut, skin, and animal cells (Sakamoto et al.,
1993; Grases et al., 2005; Vucenik and Shamsuddin, 1994). In a diet
with low consumption of InsP6, the typical level of this compound
found in human plasma is 0.1 μmol L−1, increasing to about 4 times
this amount in a normal diet (0.393 μmol L−1) (Grases et al., 2001a,
2001b). Intracellular levels of InsP6 at 11.0, 14.5, and 15.8 μmol L−1
were estimated in the cells of liver, brain and rat lung, respectively. In
HeLa cells, human cervical cancer cells, InsP6 was found at a concentra-
tion of 37.6 μmol L−1 (Letcher et al., 2008).
On the other hand, the coordination compound InsP6–Ni(II) com-
plex potentiated the antitumoral effect of InsP6 towards Jurkat cells.
Comparing the cytotoxic effect of the 2.0 mM InsP6 concentration with
the 0.22 mM InsP6–Ni(II) complex concentration, the effect of the
InsP6–Ni(II) complex on Jurkat cells was 10 times higher than that of
free InsP6 (Figs. 1 and 2). This effect was seen in both treatments during
24 and 48 h. The monitoring of the cell cycle phases for Jurkat cells re-
vealed different response proﬁles for the InsP6 and InsP6–Ni(II) complex
treatments. G1 cell cycle arrest was observed in the treatment of the
Jurkat cells with InsP6 (Table 2). These results are similar to those re-
ported by Singh et al. (2003) and Agarwal et al. (2004), who observed
that the accumulation in G1 in human prostate cancer cells was accom-
panied by a decrease in cell population in both S and G2/M phases. On
the other hand, the InsP6–Ni(II) complex treatments induced G2/M ar-
rest (Table 3). This response proﬁle presented by treatment with
InsP6–Ni(II) complex is similar to the proﬁle observed for vincristine, a
cycle-dependent antitumor agent, which was used as positive control
(Table 3). In our study, treatment with vincristine at a concentration
of 4 × 10−5 mM led to an accumulation of the cell population in the S
phase and G2/M, with a statistical difference of 29.72% in this lastTable 2
Cell cycle distribution of Jurkat cells treated with InsP6 for 24 h.
InsP6 (mmol L−1) Cell cycle distribution (%)
Sub G0# G0/G1 S G2/M
0 13.75 ± 0.33 61.62 ± 0.90 16.82 ± 0.70 21.86 ± 0.26
1.0 12.44 ± 1.26 65.16 ± 0.75 16.18 ± 0.65 18.96 ± 0.45
2.0 17.55 ± 2.98 68.23 ± 0.56a 14.83 ± 0.91 18.18 ± 0.50a
4.0 13.92 ± 1.02 67.02 ± 1.61a 14.50 ± 0.92a 18.85 ± 1.52
Results are expressed as amean± SEM (n=6). The percentage of cells distributed on cell
cycle do not include sub-Go phase and correspond to 100%.
a Statistical differences (p b 0.05) when one-way ANOVA followed by Tukey's post hoc
test was applied in relation to the control during 24 h of treatment.
# Sub G0 represents the percentage of cellswith fragmentedDNA in relation to the total
events analyzed (20,000 events).phase in relation to control. An increase in the number of apoptotic
cells was not observed for this concentration over 24 h. According to
Casado et al. (2007) and Casado et al. (2009) the treatment of MCF7
cells (breast cancer) for 48 h, and HeLa (cervical cancer) for 24 h, re-
spectively, with vincristine 1 mM led, in both cases, to induced cycle ar-
rest in G/M. The treatment also led to an increase of apoptotic cell death,
which was similar to the result observed for cells treated with InsP6–
Ni(II) complex, represented by sub-GO phase (Table 3). Sub G0 repre-
sents DNA fragmentation corresponding to total events analysis and is
an indicative of cell death induced by apoptosis.
To date, still there is no report in the literature of the antitumoral
action of InsP6–Ni(II) complex. However, studies on the antitumoral
activity for Ni(II) complexes with other ligands are available in the
literature (Tan et al., 2010; Milenković et al., 2013). Tan et al.
(2010) observed that quercetin–Ni(II) complex induced apoptosis
in dose-dependent cell lines of liver carcinoma (HepG2), human
hepatoma (SMMC7721) and lung adenocarcinoma (A549). Accord-
ing to the authors, the antitumoral activity consisted of the selective
binding of the complex with DNA, triggering a series of events that
led to cell death. Milenković et al. (2013) studied the activity of
three square planar complexes of Ni(II) with ethyl (2E)-2-[2-
(diphenylphosphino) benzylidene] hydrazinecarboxylate and
monodentate pseudohalides. They observed that all the complexes
had cytotoxic activity in relation to the six tumor cell lines that
were tested. However, the azido complex showed similar activity
to cisplatin in the leukemia cell line K562 and lower toxicity in nor-
mal MRC-5 cells.
The complex formation constant of InsP6–Ni(II) is 8.2 for the MH4L
species, a tetraprotonada InsP6 molecule coordinated to the metal ion,
that is close to 7.0 in pH (De Carli et al., 2006). A high value for the con-
stant of the formation of the complex signals that the metal ion is not
free in solution and that it is coordinated to InsP6. This information is
important because free Ni(II) in solution, per se is toxic, and promotes
oxidative stress, apoptosis, G2/M arrest and genotoxicity in normal rat
kidney cells (Chen et al., 2010; Taira et al., 2001). Ni(II) also presents
an apoptotic effect on HeLa tumor cells (Ada et al., 2010). The present
study also veriﬁed that Ni(II), in the form of NiCl2 salt, was toxic for
both normal and tumor cells (Figs. 4 and 2, respectively). Therefore, in
the InsP6–Ni(II) complex the Ni(II) ions are not free in solution; the
complex did not show a toxic effect on normal cells. However, the com-
plex showed a cytotoxic effect on tumor cells, which makes the InsP6–
Ni(II) complex more selective.
5. Conclusion
The results demonstrate that both InsP6 and InsP6–Ni(II) complex
presented cytotoxic and antiproliferative effects on human acute
Table 3
Cell cycle distribution of Jurkat cells treated with InsP6–Ni(II) complex and vincristine for 24 h.
Cell cycle distribution (%)
Treatment (mmol L−1) Sub G0# G0/G1 S G2/M
Control 14.40 ± 0.87 65.63 ± 1.55 16.63 ± 0.36 18.05 ± 1.31
InsP6–Ni(II) — 0.050 17.68 ± 6.35 62.21 ± 1.75a 20.46 ± 2.10 18.04 ± 2.46
InsP6–Ni(II) — 0.175 58.01 ± 7.55a 46.79 ± 3.37a 23.22 ± 1.66a 30.49 ± 2.19a
InsP6–Ni(II) — 0.300 54.95 ± 7.07a 56.09 ± 1.80a 21.06 ± 0.94 23.32 ± 0.88
Vincristine — 4 × 10−5 10.72 ± 0.28 31.30 ± 0.73a 21.34 ± 0.24a 47.77 ± 0.55a
Results are expressed as a mean ± SEM (n = 6). The percentage of cells distributed on cell cycle not include sub-Go phase and correspond to 100%.
a Statistical differences (p b 0.05) when one-way ANOVA followed by Tukey's post hoc test was applied in relation to the control during 24 h of treatment.
# Sub G0 represents the percentage of cells with fragmented DNA in relation to the total events analyzed (20,000 events).
2087E.M. de Lima et al. / Toxicology in Vitro 29 (2015) 2081–2088leukemia Jurkat T cells. The InsP6–Ni(II) complex was more active to-
wards Jurkat T cells as compared to InsP6 and potentiates the antitumor
effects of free InsP6. The results also showed that the primary culture of
human normal lymphocytes are more refractory to the cytotoxic effect
of InsP6–Ni(II) complex compared to Jurkat T cells, which may allow a
better application of the antitumor agent. The cytometric ﬂow assay
showed that InsP6 led to accumulation of cells in the G0/G1 phase of
the cell cycle, accompanied by a decrease in the number of cells in S
and G2/M phases, whereas InsP6–Ni(II) complex has led to an accumu-
lation of cells in the S and G2/M phases. The present study reports for
the ﬁrst time in the literature the in vitro anticancer activity of InsP6–
Ni(II) complex. Further experiments have been conducted by our
group to verify the action of the InsP6–Ni(II) complex in other types of
tumors cells and also other metallic InsP6 complexes, namely InsP6–
Co(II) and InsP6–Mn(II), to contribute to the elucidation of the mecha-
nisms involved in such a bioactivity.
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